Neoadjuvant Chemotherapy of Primary Breast Cancer With Epirubicin/Docetaxel and Carboplatin/Docetaxel

• Status: Completed
• Trial end date: 2008-09-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is to optimize results in neoadjuvant chemotherapy of local advanced primary breast cancer. Therefore patients become first 3 cycles of Epirubicin/Docetaxel followed by 3x Carboplatin/Docetaxel.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Klinikum Weissenfels
• Treatments: Carboplatin; Docetaxel; Epirubicin

Criteria

Inclusion Criteria:

• histologically assured breast cancer

• age >= 18 years

• bone marrow function: neutrophils >= 1.5x109/l, platelets >= 100x109/l, hemoglobin >=6.2 mmol/l

• sufficient renal and liver function

• ECOG 0-2

• written informed consent

Exclusion Criteria:

• pregnant or nursing women

• distant metastases

• T2-Tumour < 3cm and G1

• existing motoric or sensoric neurotoxicity > Grade 2

• known hypersensitivity against Epirubicin or other anthracycline or against Carboplatin or other platin derivatives or against Docetaxel or against substances in the preparing solutions